Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893348 | 0.83 | GAA (0.56) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| SCHEMBL9924006 | 0.79 | ALDH1A1 (0.43) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| SCHEMBL9893404 | 0.78 | ALDH1A1 (0.46) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| SCHEMBL9893209 | 0.77 | NTRK1 (0.47) | RAB9ASMN1; SMN2KMT2AGAANTRK1 | |
| SCHEMBL9924007 | 0.76 | PTGS1 (0.66) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| Hydrochloric Acid SCHEMBL28455052 | 0.74 | PTGS1 (0.64) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| Hydrochloric Acid SCHEMBL18131886 | 0.71 | NPC1 (0.50) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| SCHEMBL15004600 | 0.71 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| SCHEMBL13325706 | 0.70 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2KMT2AGAA | |
| SCHEMBL9981033 | 0.69 | SMN1; SMN2 (0.58) | RAB9ANPC1SMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-8618150-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-2649072-A1 | IMIDAZO [1, 2-A]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078994-A1 | IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | RAB9A 661/4885NPC1 1267/4885SMN1; SMN2 442/4885 |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | RAB9A 661/4885NPC1 1267/4885SMN1; SMN2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.